Skip to main content
Back to feed
HealthSingle-sourceMedium
5.2

GSK acquires Chimagen TCE for $750M, underscores China biotech rise

GSK licensed global rights to Chimagen Biosciences' T-cell engager for multiple myeloma in a deal worth up to $750M. This marks a significant cross-border pharma deal highlighting China's growing biotech innovation. The deal's success depends on clinical trial outcomes and regulatory approvals.

South China Morning Postabout 7 hours agoGB, CNengCredibility 28%View source

Score Breakdown

Mosaic Score5.2
Confidence0.9
Significance0.5
Source credibility0.3

Intelligence Tags

#biotech#pharma#licensing#cancer#china#gsk

Locations

Chengdu

Entities

countrycountry
Source

Related signals

8 found